Business
Helix BioPharma awarded first U.S. Patent for DOS47
Helix BioPharma awarded first U.S. Patent for DOS47.
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\nAURORA, ON, May 3 /CNW/ - Helix BioPharma Corp. (TSX: HBP / Frankfurt:\nWKN 918864) announced today the issuance of a patent (U.S. Patent No.\n7,211,250) from the United States Patent & Trademark Office relating to the\nmethod and composition in combining DOS47 with targeting agents in the\ntreatment of cancer. Helix is currently developing its first DOS47-based\ncancer therapeutic, L-DOS47, a drug product candidate for the treatment of\nadenocarcinoma of the lung.\n\n\n"This patent provides Helix with significant intellectual property\nprotection and is a vital step toward our goal of bringing DOS47-based cancer\ntherapeutics to market," said Donald H. Segal, President and CEO of Helix. "We\nwill continue to advance our worldwide DOS47 patent strategy in support of the\ndevelopment of L-DOS47 with a view to maximizing the commercial opportunity of\nthis product and future products derived from our DOS47 technology platform."\n\n\nPreliminary in vitro and in vivo testing of L-DOS47 has been completed\nwith certain research findings presented in peer-reviewed publications,\nposters and scientific meetings. See our website at www.helixbiopharma.com for\nfurther information on these publications, posters and meetings. In addition,\nHelix has begun scale-up manufacturing of L-DOS47 for the Company's upcoming\npreclinical and clinical testing initiatives.\n\n\n"Though we are focused on L-DOS47 as our first DOS47-based cancer\ntherapeutic, we continue to explore other cancer-specific targeting agents\nwith the goal of developing a portfolio of conjugated DOS47-based cancer\ntherapeutics," commented Dr. Heman Chao, Helix's Vice President of Research.\n\n\nAbout L-DOS47\n\n\nL-DOS47 combines Helix's proprietary DOS47 new drug candidate with a\nhighly specific single domain antibody, to form a potential new targeted drug\nproduct for the treatment of adenocarcinoma of the lung, the most common form\nof cancer in the world today. L-DOS47 is thought to function by leveraging a\nnatural process in the body called the urea cycle, to produce an anti-cancer\neffect. It is based upon a naturally occurring enzyme called urease that\nessentially reverses the urea cycle by breaking down urea into metabolites\nthat include ammonia and hydroxyl ions. By doing so at the site of cancerous\ntissues in the body,...